Raymond James & Associates Leap Therapeutics, Inc. Transaction History

Raymond James & Associates

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 14, 2023	SELL	$0.29 - $0.72 $1,160 - $2,880	-4,000 Reduced 11.88%	29,678 $10,000
Q4 2022 Feb 08, 2023	SELL	$0.42 - $9.18 $7,584 - $165,781	-18,059 Reduced 34.91%	33,678 $15,000
Q3 2022 Oct 25, 2022	BUY	$0.92 - $9.3 $460 - $4,650	500 Added 0.98%	51,737 $46,000
Q2 2022 Aug 12, 2022	BUY	$0.96 - $1.91 $7,384 - $14,691	7,692 Added 17.66%	51,237 $59,000
Q1 2022 May 11, 2022	BUY	$1.6 - $3.35 $13,396 - $28,049	8,373 Added 23.81%	43,545 $76,000
Q4 2021 Feb 08, 2022	BUY	$2.08 - $3.65 $73,157 - $128,377	35,172 New	35,172 $114,000
Q4 2020 Feb 12, 2021	SELL	$1.49 - $2.37 $49,319 - $78,447	-33,100 Closed	0 $0
Q3 2020 Nov 04, 2020	BUY	$1.68 - $2.17 $1,932 - $2,495	1,150 Added 3.6%	33,100 $66,000
Q2 2020 Jul 28, 2020	BUY	$1.39 - $2.84 $44,410 - $90,738	31,950 New	31,950 $67,000

265K

Ticker LPTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,021,400
Market Cap $344M
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate can...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.